{"url_path":"/sec/bbot/8-k/2026-05-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219801-index.html","accession_number":"0001193125-26-219801","cik":"0001869105","ticker":"BBOT","issuer_name":"BridgeBio Oncology Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219801-index.html","primary_entity_key":"0001869105","primary_entity_name":"BridgeBio Oncology Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit No.\n\n \n\nDescription\n\n \n\n \n\n99.1\n\n \n\n[Press release dated May 12, 2026](bbot-ex99_1.htm).\n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nBRIDGEBIO ONCOLOGY THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Pedro J. Beltran\n\n \n\nName:\n\nPedro J. Beltran, Ph.D.\n\n \n\nTitle:\n\nChief Executive Officer"}